NIH Awards Invistics Grant to Expand Drug Diversion Program in Hospitals
ATLANTA, GA Oct 03, 2018
Invistics, the leading provider of advanced healthcare inventory visibility and analytics software, today announced that the National Institutes of Health (NIH) has awarded the company a supplementary grant, expanding its drug diversion program. The program leverages machine learning and advanced analytics to detect opioid and drug theft across entire hospitals and systems, improving patient safety, reducing financial risk and protecting healthcare workers.
Invistics has seen early success in Piedmont Athens Regional Medical Center and other pilot hospitals, expediting the phase II grant timing and expansion into anesthesiology. The program currently tracks and identifies drug diversion across nursing and pharmacy departments. Studies have found that roughly 10 percent of the nation’s nurses, anesthesiologists and pharmacists are currently diverting drugs in their workplaces.
“Piedmont Healthcare is focused on building a strong response to the opioid crisis, and we’re extremely proud of our hospital’s unique and proactive drug diversion program,” said Dr. Charles Peck, president and CEO of Piedmont Athens Regional, which serves as the 11-hospital system’s east hub. “Invistics provides us with unprecedented interdepartmental transparency and strategic analysis – they have certainly helped to elevate our program to one of the strongest in the country.”
The average mid-size 500-bed hospital has approximately 25 to 75 people at risk for diverting at any time, while only five or fewer diversions are investigated annually, according to studies. According to a recent Porter Research study, 66 percent of respondents felt their programs were neither efficient nor effective, and yet nearly all believe their strategy is on par or better than their peers.
“Opiate theft and other drug diversion is a very real industry threat – one that is incredibly challenging to identify and prevent, and yet directly impacts our ability to ensure the highest quality patient care,” said Tom Knight, founder and CEO of Invistics. “With the support of NIH and our hospital partners, we hope providers can proactively prevent drug diversion, something that simply isn’t possible solely with manual processes and investigation.”
Invistics is a cloud-based solution that enables tracking of opioids and other drugs through the complex pharmaceutical supply chain and offers near real-time intelligence, pulling from thousands of data markers across the entire enterprise. The National Institute on Drug Abuse (NIDA), an entity of NIH, awarded Invistics the first research grant in 2017, for which the company aggregated data from across the partnering hospital’s systems including its medical records, employee time clocks, wholesale purchasing, inventory and dispensing cabinets.
Invistics officially launched its drug detection software to all hospitals and health systems across the U.S. in 2018.